Runnymede Capital Advisors’s Viking Therapeutics VKTX Stock Holding History

Runnymede Capital Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,990	Closed	-$145K	–	262
2025 Q1	$145K	Sell	5,990 -300	-5%	-$9.48K	0.14%	82
2024 Q4	$253K	Buy	+6,290	New	+$359K	0.22%	64

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Runnymede Capital Advisors's VKTX Position: Q2 2025 in Review

Runnymede Capital Advisors sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 5,990 shares — an estimated $145K sold.

Runnymede Capital Advisors first reported a position in VKTX in Q4 2024 and held it in 2 quarters. The position peaked at $253K in Q4 2024. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

Runnymede Capital Advisors reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
Runnymede Capital Advisors sold 5,990 Viking Therapeutics shares in Q2 2025, an estimated $145K.
Runnymede Capital Advisors first reported a position in Viking Therapeutics in Q4 2024 and held it in 2 quarters.
Runnymede Capital Advisors's Viking Therapeutics position peaked at $253K in Q4 2024.
391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Runnymede Capital Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.